连花清瘟颗粒等8种中药体外抗新型冠状病毒活性以及细胞毒性研究

Antiviral Activity Research of Lianhuaqingwen and Other Seven Traditional Chinese Medicine to SARS-CoV-2

为了评估连花清瘟颗粒等中药(Traditional Chinese Medicines,TCMs)体外的抗新型冠状病毒作用。采用Cell Counting Kit-8(CCK8)法检测药物对Vero细胞的毒性,确定药物的细胞毒性。再以Vero细胞为模型,设置药物组、瑞德西韦对照组、病毒对照组,用新型冠状病毒感染细胞,药物作用48 h,提取核酸,用荧光定量PCR法检测新型冠状病毒RNA拷贝数,评估药物的抗病毒作用。细胞活性结果和病毒RNA拷贝数变化的结果显示,连花清瘟等8种药物中,连花清瘟抗新型冠状病毒活性较好,半数抑制浓度达到了0.43 mg/mL,药物六神丸和藿香正气水的细胞毒性较大,其他5种药物的抗新型冠状病毒活性较低。本研究揭示了莲花清瘟等8种药物体外的抗新型冠状病毒效果,为进一步的研究奠定了基础。

In order to investigate the antiviral activity of Lianhuaqingwen and other 7 traditional Chinese medicines(TCMs)to severe acute respiratory syndrome coronavirus 2(SARS-CoV-2). Cell Counting Kit-8(CCK8) method was used to access the toxicity of drugs on Vero cells. Vero cell as in vitro model,were infected with SARS-CoV-2,TCMs or Remdesivir were added to cells. After 48 hours,nucleic acids were extracted and SARS-COV-2 RNA copies were accessed by qRT-PCR to evaluate drug effect. Among the 8 TCMs,Lianhuaqingwen had a significant antiviral activity to SARS-CoV-2 and its half-maximal effective concentration(EC_(50))was 0.43 mg/mL. Liushenwan and Huoxiangzhengqishui had high cytotoxicity,while the other 5 had low antiviral activity. Among 8 TCMs,our data shown Lianhuaqingwen has a significant antiviral to SARS-CoV-2 and lay the foundation for further study.